Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.

ABSTRACT: The chemokine receptor, CXCR4, is involved in cancer growth, invasion, and metastasis. Several promising CXCR4 antagonists have been shown to halt tumor metastasis in preclinical studies, and clinical trials evaluating the effectiveness of these agents in patients with cancer are ongoing. However, the impact of targeting CXCR4 specifically on immune cells is not clear. Here, we demonstrate that genetic deletion of CXCR4 in myeloid cells (CXCR4^MyeΔ/Δ) enhances the antitumor immune response, resulting in significantly reduced melanoma tumor growth. Moreover, CXCR4^MyeΔ/Δ mice exhibited slowed tumor progression compared with CXCR4^WT mice in an inducible melanocyte Braf^V600E/Pten ^-/- mouse model. The percentage of Fas ligand (FasL)-e

SUBMITTER: Yang J 

PROVIDER: S-EPMC6170679 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature